| Field | Specification |
|---|---|
| Target | |
| Alternative names | Scaffold attachment factor B1;SAF-B;SAF-B1;HSP27 estrogen response element-TATA box-binding protein;HSP27 ERE-TATA-binding protein;SAFB;HAP, HET, SAFB1; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human SAFB, different from the related mouse and rat sequences by five amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes scaffold attachment factor B1 (gene SAFB) in human and mouse samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 102.6 kDa, and the supplier reports an observed band at about 150 kDa.
SAFB (scaffold attachment factor B1) is a nuclear protein that binds matrix attachment region DNA and helps link transcription with RNA processing. It acts as a corepressor of estrogen receptor signaling and represses the stress gene HSP27, and it is studied in breast cancer biology and chromatin organization.
| Target | Scaffold attachment factor B1 (gene SAFB; UniProt Q15424, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 102.6 kDa |
| Observed MW | 150 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Mouse) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
Samples with a confirmed band (WB): human K562 cells, human Caco-2 cells, human PC-3 cells, human MCF-7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 8% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human colon cancer tissue, human tonsil tissue, human prostate cancer tissue, mouse brain tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): T47D cells.
Samples with confirmed staining (ICC/IF): human colon cancer tissue.
Immunogen
Synthetic peptide from the C-terminal region of human SAFB. It differs from the mouse and rat sequences at five residues.
Reactivity Notes
The supplier lists reactivity with human and mouse. UniProt places scaffold attachment factor B1 in the nucleus. Tissue expression noted by UniProt (human): Ubiquitous. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
